Endpoint Validation Study (0524A-015)

This study has been completed.

Sponsor:

Merck Sharp & Dohme Corp.

ClinicalTrials.gov Identifier:

NCT00533676

First Posted: September 21, 2007

Last Update Posted: February 17, 2017

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 70 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patients must be male or female between 18 to 70 years

Qualified women must be sterile (through surgery) and/or post-menopausal, and/or agree to use birth control

Exclusion Criteria:

You are a woman who is having hot flashes, receiving Hormone Replacement Therapy (HRT), and/or other therapies for hot flashes

You are currently using Niacin/or Niacin containing products with a daily dose over 50 mg/day

You are sensitive to niacin

You have a history gout

You drink more than 2 glasses of alcohol per day and you are not willing to stop

You don't have access to a telephone

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00533676